Abstracts tagged "gout"

Abstract Number: 226 • 2015 ACR/ARHP Annual Meeting
Prevalence of Cardiovascular Disease in Patients with Gout, Osteoarthritis or Both
Daisy Bang¹, Jinfeng Xu², Robert T. Keenan³, Virginia Pike¹, Aaron Lehmann¹, Craig T. Tenner⁴, Daria Crittenden¹, Michael H. Pillinger¹ and Svetlana Krasnokutsky¹, ¹Medicine/Rheumatology, NYU School of Medicine/NYU Hospital for Joint Diseases, New York, NY, ²Biostatistics, New York University School of Medicine, New York, NY, ³Rheumatology, Duke University, Durham, NC, ⁴Medicine, NYU School of Medicine, New York, NY
Background/Purpose: Osteoarthritis (OA) and gout are each associated with increased cardiovascular disease (CVD), but their relative impacts on CV risk are not known. We compared…
Abstract Number: 2108 • 2015 ACR/ARHP Annual Meeting
A Pragmatic Cluster-Randomized Controlled Trial of an Automated, Pharmacy-Based Intervention to Optimize Allopurinol Therapy in Gout
Ted R. Mikuls¹, T C Cheetham², Nazia Rashid², Gerald D. Levy³, Artak Kerimian⁴, KJ Low², Brian Coburn⁵, David T. Redden⁶, S. Louis Bridges Jr.⁷, Kenneth G. Saag⁶ and Jeffrey R. Curtis⁷, ¹Medicine, University of Nebraska Medical Center, Omaha, NE, ²Pharmacy Analytical Services, Kaiser Permanente Southern California, Downey, CA, ³Rheumatology, Kaiser Permanente Southern California, Downey, CA, ⁴Ambulatory Care Pharmacy, Kaiser Permanente Southern California, Downey, CA, ⁵Internal Medicine - Rheumatology, University of Nebraska Medical Center, Omaha, NE, ⁶University of Alabama at Birmingham, Birmingham, AL, ⁷Clinical Immunology and Rheumatology, University of Alabama at Birmingham, Birmingham, AL
Background/Purpose: Gout is a common form of inflammatory arthritis, often treated with allopurinol as a first-line urate lowering therapy. We have designed a large…
Abstract Number: 2353 • 2015 ACR/ARHP Annual Meeting
Lesinurad and Febuxostat Combination Therapy: Analysis of Treatment Based on Patient Baseline Renal Function
Nicola Dalbeth¹, Graeme Jones², Robert Terkeltaub³, Dinesh Khanna⁴, Jeff Kopicko⁵, Scott Adler⁶, Nihar Bhakta⁵, Maple Fung⁵, Chris Storgard⁵, Scott Baumgartner⁵ and Fernando Perez-Ruiz⁷, ¹Department of Medicine, University of Auckland, Auckland, New Zealand, ²Musculoskeletal Unit, Menzies Institute for Medical Research, University of Tasmania, Hobart, Australia, ³Medicine-Rheumatology, University of California, San Diego, La Jolla, CA, ⁴Div of Rheumatology, University of Michigan, Ann Arbor, MI, ⁵Ardea Biosciences, Inc., San Diego, CA, ⁶AstraZeneca Pharmaceuticals, Wilmington, DE, ⁷Servicio de Reumatologia, Hospital Universitario Cruces, Baracaldo, Spain
Background/Purpose: A randomized, double-blind, placebo-controlled, Phase III clinical trial showed that lesinurad, a selective uric acid reabsorption inhibitor (SURI), in combination with febuxostat 80 mg…
Abstract Number: 227 • 2015 ACR/ARHP Annual Meeting
Impact of Gout on the Risk of Atrial Fibrillation
Chang-Fu Kuo¹, Matthew J. Grainge², Weiya Zhang³ and Michael Doherty⁴, ¹Division of Rheumatoplogy, Allergy and Immunology, Chang Gung Memorial Hospital, Tayuan, Taiwan, ²Division of Epidemiology and Public Health, School of Community Health Sciences, University of Nottingham, Nottingham, United Kingdom, ³Academic Rheumatology, School of Clinical Sciences, University of Nottingham, Nottingham, United Kingdom, ⁴Academic Rheumatology, City Hospital, Nottingham, United Kingdom
Background/Purpose: To examine the risk of atrial fibrillation (AF) at the time of first diagnosis of gout compared to matched controls and to follow incident…
Abstract Number: 2112 • 2015 ACR/ARHP Annual Meeting
Analysis of Gout Subjects Receiving Lesinurad and Allopurinol Combination Therapy By Baseline Renal Function
Kenneth G. Saag¹, Thomas Bardin², Alexander So^3,4, Puja Khanna⁵, Chris Storgard⁶, Scott Baumgartner⁷, Maple Fung⁷, Nihar Bhakta⁷, Scott Adler⁸, Jeff Kopicko⁷ and Michael A. Becker⁹, ¹University of Alabama at Birmingham, Birmingham, AL, ²Lariboisière Hospital, Paris, France, ³Rheumatology, Centre Hospitalier Universitaire Vaudois, University of Lausanne, Lausanne, Switzerland, ⁴CHU Vaudois, University of Lausanne, Lausanne, Switzerland, ⁵Division of Rheumatology/Dept. of Internal Medicine, University of Michigan Medical Center, Ann Arbor, MI, ⁶4939 Directors Place, Ardea Biosciences, Inc., San Diego, CA, ⁷Ardea Biosciences, Inc., San Diego, CA, ⁸AstraZeneca Pharmaceuticals, Wilmington, DE, ⁹University of Chicago, Chicago, IL
Background/Purpose: Two randomized, double-blind, placebo-controlled Phase III clinical trials showed that lesinurad (200 or 400 mg) when added to allopurinol (200-900 mg) significantly increased the…
Abstract Number: 2354 • 2015 ACR/ARHP Annual Meeting
The Safety and Efficacy of Lower Serum Urate Levels: A Pooled Analysis of Gout Subjects Receiving Lesinurad and Xanthine Oxidase Inhibitors
Robert Terkeltaub¹, Fernando Perez-Ruiz^2,3,4, Jeff Kopicko⁵, Maple Fung⁵, Scott Adler⁶, Chris Storgard⁷, Scott Baumgartner⁵ and Nicola Dalbeth⁸, ¹Medicine-Rheumatology, University of California, San Diego, La Jolla, CA, ²Rheumatology Division, Hospital Universitario Cruces, Barakaldo, Spain, ³BioCruces Health Research Institute, Baracaldo, Spain, ⁴Servicio de Reumatologia, Hospital De Cruces, Baracaldo, Spain, ⁵Ardea Biosciences, Inc., San Diego, CA, ⁶AstraZeneca Pharmaceuticals, Wilmington, DE, ⁷4939 Directors Place, Ardea Biosciences, Inc., San Diego, CA, ⁸Department of Medicine, University of Auckland, Auckland, New Zealand
Background/Purpose: Previous studies have shown that long-term urate-lowering therapy (ULT) is required for improvements in gout flare frequency and tophi reduction, and that lower serum…
Abstract Number: 231 • 2015 ACR/ARHP Annual Meeting
Uric Acid Levels Predict Mortality in Women
Jenni E Kauppi¹, Tuomo Nieminen^2,3, Mika Kähönen^4,5, Anne Kerola⁶, Antti Jula⁷, Jaana Leiviskä⁸ and Markku J. Kauppi^9,10, ¹School of medicine, University of Tampere, Tampere, Finland, ²Department of Internal Medicine, South Karelia Central Hospital, Lappeenranta, Finland, ³Division of Cardiology, Helsinki University Central Hospital, Helsinki, Finland, ⁴Department of Clinical physiology, School of Medicine, University of Tampere, Tampere, Finland, ⁵Department of Clinical Physiology, Medical Imaging Centre, Pirkanmaa Hospital District, Tampere, Finland, ⁶Faculty of Medicine, University of Helsinki, Helsinki, Finland, ⁷Department of Health, National Institute for Health and Welfare, Turku, Finland, ⁸Department of Health, National Institute for Health and Welfare, Helsinki, Finland, ⁹School of Medicine, University of Tampere, Tampere, Finland, ¹⁰Department of Rheumatology, Päijät-Häme Central Hospital, Lahti, Finland
Background/Purpose: Hyperuricemia induces chronic inflammation and is associated with many diseases such as metabolic syndrome, high blood pressure, chronic kidney disease and cardiovascular diseases. The…
Abstract Number: 2113 • 2015 ACR/ARHP Annual Meeting
Lesinurad, a Novel Selective Uric Acid Reabsorption Inhibitor, in Combination with Febuxostat, in Patients with Tophaceous Gout
Nicola Dalbeth¹, Graeme Jones², Robert Terkeltaub³, Dinesh Khanna⁴, Jeff Kopicko⁵, Nihar Bhakta⁵, Maple Fung⁵, Chris Storgard⁶, Scott Baumgartner⁵ and Fernando Perez-Ruiz⁷, ¹Department of Medicine, University of Auckland, Auckland, New Zealand, ²Musculoskeletal Unit, Menzies Institute for Medical Research, University of Tasmania, Hobart, Australia, ³Medicine-Rheumatology, University of California, San Diego, La Jolla, CA, ⁴Div of Rheumatology, University of Michigan, Ann Arbor, MI, ⁵Ardea Biosciences, Inc., San Diego, CA, ⁶4939 Directors Place, Ardea Biosciences, Inc., San Diego, CA, ⁷Servicio de Reumatologia, Hospital Universitario Cruces, Baracaldo, Spain
Background/Purpose: Lesinurad (LESU; RDEA594) is a selective uric acid reabsorption inhibitor (SURI) being investigated for the treatment of gout in combination with a xanthine oxidase…
Abstract Number: 3165 • 2015 ACR/ARHP Annual Meeting
Do Omega-3 Fatty Acids Reduce Risk of Recurrent Gout Attacks?
MaryAnn Zhang¹, Yuqing Zhang², Robert Terkeltaub³, Clara Chen⁴ and Tuhina Neogi², ¹Internal Medicine, Boston University School of Medicine, Boston, MA, ²Boston University School of Medicine, Boston, MA, ³Medicine-Rheumatology, VA Medical Ctr/University of California San Diego, San Diego, CA, ⁴Boston University School of Public Health, Boston, MA
Background/Purpose: Current guidelines for gout management, based in part on epidemiologic data for development of incident gout, recommend limiting intake of high-purine fish. However,…
Abstract Number: 233 • 2015 ACR/ARHP Annual Meeting
Gout Does Not Decrease the Risk of Parkinson’s Disease: A Systematic Review and Meta-Analysis
Patompong Ungprasert¹, Charat Thongprayoon² and Narat Srivali³, ¹Rheumatology, Mayo Clinic, Rochester, MN, ²Internal medicine, Bassett medical center, Cooperstown, NY, ³Pulmonary and Critical Care Medicine, Mayo Clinic, Rochester, MN
Gout Does Not Decrease the Risk of Parkinson's Disease: A Systematic Review and Meta-analysisBackground/Purpose: Uric acid is a potent anti-oxidant and hyperuricemia is well-linked to…
Abstract Number: 2228 • 2015 ACR/ARHP Annual Meeting
Brief Educational Intervention Improves Gout Patients’ Understanding of Their Disease
Slavica Bobic¹, Mark Tratenberg¹, Julia Ash¹, Amy Wasserman² and Kirk Sperber¹, ¹Rheumatology, New York Medical College, Valhalla, NY, ²New York Medical College, Valhalla, NY
Background/Purpose: To assess gout patients’ baseline knowledge of their disease and to measure knowledge improvement after brief educational session. Methods: In this study, 13 patients…
Abstract Number: 3167 • 2015 ACR/ARHP Annual Meeting
Association of the Apolipoprotein A1-C3-A4 Gene Cluster with the Risk of Gout: Evidence for a Causal Role in Gout
Tony R. Merriman¹, Amanda Phipps-Green², Ruth Topless², Malcolm D. Smith³, Catherine Hill⁴, Susan Lester⁴, Maureen Rischmueller⁵, Matthijs Janssen⁶, Tim Jansen⁷, Leo A. Joosten⁸, Timothy Radstake⁹, Philip L. Riches¹⁰, Anne-Kathrin Tausche¹¹, Frederic Lioté¹², Alex So^13,14, Andre M. van Rij², Gregory T. Jones¹⁵, Sally McCormick¹⁶, Andrew Harrison², Lisa K. Stamp¹⁷, Nicola Dalbeth¹⁸ and Humaira Rasheed¹⁶, ¹Biochemistry Dept, PO Box 56, University of Otago, Dunedin, New Zealand, ²University of Otago, Dunedin, New Zealand, ³Rheumatology, Repatriation General Hospital, Adelaide, Australia, ⁴Rheumatology Unit, The Queen Elizabeth Hospital, Woodville, Australia, ⁵Rheumatology, Queen Elizabeth Hospital, Adelaide, Australia, ⁶Rheumatology Dept, Ziekenhuis Rijnstate, Arnhem, Netherlands, ⁷P O Box 581, Haarlem, Netherlands, ⁸Department of Medicine, Radboud University Nijmegen Medical Centre, Nijmegen, Netherlands, ⁹Radboud University Nijmegen Medical Centre, Nijmegen, Netherlands, ¹⁰Centre for Genomic and Experimental Medicine, Western General Hospital, Edinburgh, United Kingdom, ¹¹Medizinische Klinik und Poliklinik III, Universitätsklinikum Carl Gustav Carus an der Technischen Universität Dresden, Dresden, Germany, ¹²Rheumatology Department; Inserm UMR-S606; Paris-Diderot University, hôpital Lariboisiere, Paris, France, ¹³Service De Rhumatologie, CHUV, Lausanne, Switzerland, ¹⁴Department of Rheumatology, CHUV, Lausanne, Switzerland, ¹⁵Surgery, University of Otago, Dunedin, New Zealand, ¹⁶Department of Biochemistry, University of Otago, Dunedin, New Zealand, ¹⁷Medicine, University of Otago, Christchurch, Christchurch, New Zealand, ¹⁸Department of Medicine, University of Auckland, Auckland, New Zealand
Background/Purpose: Gout is caused by an inflammatory response to monosodium urate (MSU) crystals and is associated with elevated triglyceride and very low density lipoprotein levels.…
Abstract Number: 235 • 2015 ACR/ARHP Annual Meeting
Relationship Between Tissue Stress during Gait and Patterns of Urate Deposition and Bone Erosion in Gout: A Biomechanical Computational Modelling Study
Nicola Dalbeth¹, Michelle Deacon², Gregory Gamble¹, Kumar Mithraratne² and Justin Fernandez², ¹Department of Medicine, University of Auckland, Auckland, New Zealand, ²University of Auckland, Auckland, New Zealand
Background/Purpose: Gout typically presents at characteristic sites such as the 1st metatarsophalangeal joint, midfoot or ankle. A potential explanation for this distribution is that tissue…
Abstract Number: 2237 • 2015 ACR/ARHP Annual Meeting
Effects of Coffee Consumption on Serum Uric Acid. a Systematic Review and Meta-Analysis
Jae-Bum Jun¹, Shin-Young Yim², Hyun Jung Kim³, Kyu Yong Park⁴, Hyeong Sik Ahn³, Sun Hee Kim⁴ and Eun Ji Park⁴, ¹Rheumatology, Hanyang University Hospital for Rheumatic Diseases, Seoul, South Korea, ²Department of Physical Medicine and Rehabilitation, Ajou University School of Medicine, Suwon, South Korea, ³Department of Preventive Medicine, Korea University College of Medicine, Seoul, South Korea, ⁴Department of Physical Medicine and Rehabilitation, Ajou University Hospital, Suwon, South Korea
Background/Purpose: Findings on the effect of coffee consumption on serum uric acid has been conflicting. The aim of this systematic review and meta-analysis is to analyze…
Abstract Number: 238 • 2015 ACR/ARHP Annual Meeting
Relationship Between Ultrasonographic Synovial Inflammation and Ultrasonographic Urate Deposition Findings in Patients with Gout
Fernando Perez-Ruiz^1,2, Sandra P. Chinchilla-Gallo³, Irati Urionagüena⁴ and Elena Garmendia^3,5, ¹Rheumatology Division, Hospital Universitario Cruces, Barakaldo, Spain, ²BioCruces Health Research Institute, Baracaldo, Spain, ³Rheumatology Division, Hospital Universitario Cruces, Baracaldo, Spain, ⁴Rheumatology Division, Hospital Universitario ruces, Baracaldo, Spain, ⁵Biocruces Helath Research Institute, Baracaldo, Spain
Background/Purpose: urate intra-articular deposits are seen in ultrasound as double contour sign (DCS), and hyperechogenic aggregates and tophi, but the extent of contribution of any…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

ACR Abstract Embargo Policy

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. Academic institutions, private organizations and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part a scientific presentation or presentation of additional new information that will be available at the time of the meeting) is under embargo until Saturday, November 11, 2023.

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying financial and other sponsors about this policy. If you have questions about the abstract embargo policy, please contact the public relations department at [email protected].

Copyright Policy

View ACR Policies.